Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells

BACKGROUND: Proteasome inhibitors are attractive cancer therapeutic agents because they can regulate apoptosis-related proteins. Bortezomib also known as Velcade(®), a proteasome inhibitor that has been approved by the food and drug administration for treatment of patients with multiple myeloma, and...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Transl Med
Main Authors: Iskandarani, Ahmad, Bhat, Ajaz A., Siveen, Kodappully S., Prabhu, Kirti S., Kuttikrishnan, Shilpa, Khan, Muzammil A., Krishnankutty, Roopesh, Kulinski, Michal, Nasr, Rihab R., Mohammad, Ramzi M., Uddin, Shahab
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2016
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784454/
https://ncbi.nlm.nih.gov/pubmed/26956626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0823-y
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki